Profusa, Inc. Common Stock (PFSA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Profusa, Inc. Common Stock (PFSA) trades at $7.57 with AI Score 25/100 (Grade F). Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors. Market cap: $8.35M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PFSA: PFSA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PFSA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PFSA: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Profusa, Inc. Common Stock (PFSA) Healthcare & Pipeline Overview
Profusa, Inc., a digital-health innovator, is developing tissue-integrating biosensors like the Lumee™ Oxygen Platform to monitor body chemistry. The company aims to provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia, positioning itself within the evolving landscape of continuous health monitoring solutions.
What Is the Investment Thesis for PFSA?
Profusa, Inc. presents a compelling, albeit high-risk, investment opportunity within the digital health sector. The company's innovative tissue-integrating biosensor technology, particularly the Lumee™ Oxygen Platform, addresses a significant need for continuous monitoring in chronic disease management. The potential for AI-powered insights derived from this continuous data stream could revolutionize personalized healthcare. However, the company's current market capitalization of $8.35M and negative P/E ratio of -0.01 highlight the early stage and speculative nature of the investment. Key value drivers include successful completion of clinical trials, regulatory approvals, and commercialization of the Lumee™ platform. Growth catalysts include partnerships with healthcare providers and expansion into new chronic disease areas. Potential risks include regulatory hurdles, competition from established medical device companies, and the need for significant capital investment to scale production and marketing efforts. The company's beta of -0.01 suggests a low correlation with the overall market, which could provide some downside protection in a market downturn.
Based on FMP financials and quantitative analysis
PFSA Key Highlights
Profusa, Inc. is focused on tissue-integrating biosensors for continuous monitoring of body chemistry.
- The Lumee™ Oxygen Platform is designed to provide AI-powered health insights for chronic conditions.
- The company targets chronic conditions such as diabetes and critical limb ischemia.
- Profusa's technology aims to provide real-time, continuous insights into key physiological parameters.
- The company's market capitalization is $0.00B with a P/E ratio of -0.01, reflecting its early stage.
Who Are PFSA's Competitors?
PFSA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $1.45 | +0.69% | $6.23M | 30 |
| ADIL Adial Pharmaceuticals, Inc. | $5.90 | +2.52% | $5.66M | 31 |
| APRE Aprea Therapeutics, Inc. | $0.64 | -4.62% | $7.92M | 30 |
| BCDA BioCardia, Inc. | $0.97 | -2.41% | $14.4M | — |
| BFRI Biofrontera Inc. | $1.48 | +4.23% | $19.0M | — |
| NEUE NeueHealth, Inc. | $6.75 | +0.00% | $60.9M | 42 |
| PARK Park Dental Partners, Inc. | $21.68 | +2.26% | $97.9M | 38 |
| NAKA Kindly MD, Inc. | $6.30 | +3.96% | $110M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PFSA's Key Strengths?
Innovative tissue-integrating biosensor technology.
- Potential for continuous, real-time monitoring of body chemistry.
- AI-powered insights for personalized healthcare.
- Focus on chronic conditions with large unmet needs.
What Are PFSA's Weaknesses?
Early-stage company with limited commercial traction.
- High regulatory hurdles for medical devices.
- Need for significant capital investment.
- Limited number of employees (2).
What Could Drive PFSA Stock Higher?
Completion of clinical trials for the Lumee™ Oxygen Platform.
- Regulatory approvals from the FDA or other regulatory agencies.
- Announcement of partnerships with healthcare providers or pharmaceutical companies.
- Development of new biosensors for other key biomarkers.
- Expansion into new geographic markets.
What Are the Key Risks for PFSA?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory delays or rejection of product approvals.
- Competition from established medical device companies.
- Technological advancements that could render their technology obsolete.
- Need for significant capital investment to scale production and marketing efforts.
- Limited number of employees may constrain growth.
What Are the Growth Opportunities for PFSA?
- Expansion into Diabetes Management: The market for diabetes management is substantial and growing, driven by the increasing prevalence of the disease globally. Profusa's Lumee™ platform could be used to continuously monitor glucose levels and provide personalized insights to patients, potentially improving glycemic control and reducing the risk of complications. The global diabetes care devices market is projected to reach $30 billion by 2028. Successful integration of Profusa's technology into diabetes management could drive significant revenue growth.
- Application in Critical Limb Ischemia (CLI): Critical limb ischemia is a severe condition characterized by reduced blood flow to the extremities, often leading to amputation. Profusa's oxygen monitoring technology could be used to assess tissue oxygenation in patients with CLI, helping to guide treatment decisions and improve outcomes. The market for CLI treatment is estimated to be worth several billion dollars annually, presenting a significant opportunity for Profusa.
- Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers could accelerate the adoption of Profusa's technology. These partnerships could provide access to a large patient base and facilitate the integration of the Lumee™ platform into existing clinical workflows. Strategic alliances with leading healthcare organizations could enhance Profusa's credibility and market reach.
- Development of New Biosensors: Profusa could expand its product portfolio by developing biosensors for other key biomarkers, such as electrolytes, hormones, and inflammatory markers. This would broaden the applicability of its technology and increase its revenue potential. The market for biosensors is projected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and point-of-care diagnostics.
- Geographic Expansion: Initially focusing on the US market, Profusa could expand its operations to other regions, such as Europe and Asia. These markets offer significant growth opportunities, particularly in countries with aging populations and increasing prevalence of chronic diseases. International expansion would require navigating different regulatory environments and establishing local partnerships.
What Are PFSA's Competitive Advantages?
- Proprietary tissue-integrating biosensor technology.
- Potential for strong patent protection.
- First-mover advantage in the continuous body chemistry monitoring space.
- AI-powered insights derived from continuous data stream.
What Does PFSA Do?
Profusa, Inc. is a digital-health company at the forefront of developing innovative biosensor technology. The company is focused on creating tissue-integrating sensors that can continuously monitor an individual's body chemistry. Their primary product, the Lumee™ Oxygen Platform, is designed to provide real-time, continuous insights into key physiological parameters. These insights are then leveraged by AI to provide actionable health information, specifically targeting individuals with chronic conditions such as diabetes and critical limb ischemia. Founded with the vision of transforming healthcare through continuous monitoring, Profusa aims to move beyond traditional, intermittent health assessments. The company's technology allows for a more proactive and personalized approach to healthcare management. By embedding sensors directly into the body, Profusa seeks to provide a more comprehensive and dynamic understanding of an individual's health status. This approach has the potential to revolutionize the way chronic diseases are managed, enabling earlier detection of complications and more effective interventions. Profusa is headquartered in EmeryVille, USA. Profusa's focus on tissue-integrating biosensors differentiates it from competitors who primarily rely on wearable or non-invasive monitoring technologies. This unique approach allows for a more direct and accurate assessment of body chemistry, providing a richer dataset for AI-driven insights. The company's commitment to continuous monitoring and AI-powered analysis positions it as a key player in the future of digital health.
What Products and Services Does PFSA Offer?
- Develop tissue-integrating biosensors for continuous monitoring of body chemistry.
- Create the Lumee™ Oxygen Platform for real-time insights into physiological parameters.
- Utilize AI to provide actionable health information based on sensor data.
- Target chronic conditions such as diabetes and critical limb ischemia.
- Offer a more proactive and personalized approach to healthcare management.
- Provide a comprehensive and dynamic understanding of an individual's health status.
How Does PFSA Make Money?
- Develop and manufacture tissue-integrating biosensors.
- Generate revenue through the sale of the Lumee™ Oxygen Platform.
- Potentially offer subscription-based services for continuous data monitoring and AI-powered insights.
- Partner with healthcare providers for integration into clinical workflows.
What Industry Does PFSA Operate In?
The medical equipment and services industry is experiencing significant growth, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in monitoring and diagnostics. The market for continuous glucose monitoring (CGM) and other wearable sensors is expanding rapidly, with companies like Dexcom and Abbott leading the way. Profusa, Inc. is positioned within this evolving landscape, focusing on tissue-integrating biosensors that offer a more direct and potentially more accurate assessment of body chemistry compared to traditional wearable devices. The company's success will depend on its ability to navigate regulatory hurdles, secure partnerships with healthcare providers, and demonstrate the clinical and economic value of its technology.
Who Are PFSA's Key Customers?
- Individuals with chronic conditions such as diabetes and critical limb ischemia.
- Healthcare providers, including hospitals, clinics, and physicians.
- Research institutions conducting clinical trials and studies.
- Potential partnerships with pharmaceutical companies for drug development and monitoring.
Insider Activity
Over the past six months, Profusa, Inc. Common Stock insiders filed 7 SEC Form 4 transactions — 0 sales and 7 purchases. On net that is roughly 27K shares acquired (about $27K) — insiders putting money in tends to read as conviction.
Financial Health
Profusa, Inc. Common Stock's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Profusa, Inc. Common Stock stands at 154.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Profusa, Inc. Common Stock (PFSA) Valuation Context
Valued at $8.35M, PFSA is classified as a micro-cap stock. Relative to its peer group, PFSA's quantitative score of 25/100 is roughly in line with the peer average of 30/100.
Company Profile
Profusa, Inc. Common Stock operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Berkeley, US. The company is led by CEO Ben Chung-Bin Hwang. PFSA has traded publicly since 2025.
PFSA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Profusa's future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively due to recent advancements in their technology, sparking excitement among investors.
- Analysts have noted an increase in partnerships that could enhance Profusa's market reach and credibility.
- The overall healthcare sector has shown resilience, which could benefit companies like Profusa that are innovating in this space.
Bear Case
- Some investors express concern over the company's cash flow management, which could impact its ability to fund ongoing projects.
- Negative sentiment has emerged regarding regulatory hurdles that may delay product launches, causing uncertainty among stakeholders.
- The competitive landscape in the biotech sector is intensifying, with many new entrants that could overshadow Profusa's offerings.
- Recent market developments have led to skepticism about the long-term viability of niche biotech firms, including Profusa, raising caution among traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PFSA Latest News
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Aug 21, 2026
-
BC-Most Active Stocks
Associated Press · Aug 18, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jul 31, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Jul 27, 2026
PFSA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PFSA.
Price Targets
Wall Street price target analysis for PFSA.
PFSA MoonshotScore
What does this score mean?
The MoonshotScore rates PFSA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Leadership: Ben Chung-Bin Hwang
CEO
Ben Chung-Bin Hwang is the CEO of Profusa, Inc. His background includes experience in managing small teams and navigating the challenges of early-stage companies. With only two employees under his management, Hwang's role is highly hands-on, encompassing strategic direction, fundraising, and operational oversight. Further details regarding his educational background and specific career history are not available.
Track Record: Due to the limited information available, it is difficult to assess Ben Chung-Bin Hwang's track record in detail. However, as CEO of Profusa, he is responsible for guiding the company through its development and commercialization efforts. Key milestones under his leadership would include securing funding, advancing the Lumee™ Oxygen Platform through clinical trials, and obtaining regulatory approvals. The success of Profusa will ultimately depend on his ability to execute the company's strategic vision and navigate the competitive landscape.
PFSA Healthcare Stock FAQ
What does the AI Score mean for PFSA?
PFSA holds an AI Score of 25/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors. Their Lumee™ Oxygen Platform aims to continuously monitor body chemistry and provide AI-powered health …
What does Profusa, Inc. Common Stock do?
Profusa, Inc. is a digital-health company focused on developing and commercializing tissue-integrating biosensors. Their primary product, the Lumee™ Oxygen Platform, is designed to continuously monitor an individual's body chemistry, providing real-time insights into key physiological parameters.
What do analysts say about PFSA stock?
Currently, there is no available analyst coverage for Profusa, Inc. Common Stock (PFSA). The company's market capitalization of $8.35M and negative P/E ratio of -0.01 suggest that it is an early-stage, speculative investment. Potential investors should conduct their own thorough due diligence and consider the company's financial condition, regulatory risks, and competitive landscape before making any investment decisions.
What are the main risks for PFSA?
Profusa, Inc. faces several significant risks, including regulatory hurdles, competition from established medical device companies, and the need for substantial capital investment. The company's tissue-integrating biosensor technology requires regulatory approval from agencies such as the FDA, which can be a lengthy and expensive process. Competition from larger, more established companies with greater resources poses a threat to Profusa's market share.
How does Profusa, Inc. Common Stock navigate regulatory approval processes?
As a medical device company, Profusa, Inc. must navigate stringent regulatory approval processes in the United States and other markets. This typically involves conducting clinical trials to demonstrate the safety and efficacy of its Lumee™ Oxygen Platform, as well as preparing detailed submissions to regulatory agencies such as the FDA.
How does Profusa, Inc. Common Stock manage patent expiration risks?
As a company developing innovative medical technology, Profusa, Inc. relies on patent protection to safeguard its intellectual property and maintain a competitive advantage. The company must actively manage its patent portfolio, including filing new patent applications, monitoring competitor activity, and enforcing its patent rights.
What are the key factors to evaluate for PFSA?
Profusa, Inc. Common Stock (PFSA) holds an AI score of 25/100 (low). presents a compelling, albeit high-risk, investment opportunity within the digital health sector. Not financial advice.
How frequently does PFSA data refresh on this page?
PFSA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PFSA's recent stock price performance?
Profusa, Inc. Common Stock (PFSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative tissue-integrating biosensor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- AI analysis pending for PFSA.